LB Pharmaceuticals Inc Common Stock (LBRX) Stock
Key stats
- Market cap
- $1.27B
- Price / Earnings ratio
- -14.8x
- EPS (TTM)
- -$176.15
- Volume
- Loading
- 52-week high
- $50.16
- 52-week low
- $14.32
- EPS vs analyst estimate
- -7.0%Q3 FY25 · -$0.61 vs -$0.57
- Next earnings report
- 5 Nov 2026
Source: third-party data provider, as of October 23, 2026
EPS estimate: analyst consensus
Compare with LBRX
Recent news

IPO Stock LB Pharma Has Tripled In Under A Year. Is It A Takeover Target?
IPO Stock LB Pharma Has Tripled In Under A Year. Is It A Takeover Target?
LBRX

All You Need to Know About LB Pharmaceuticals Inc (LBRX) Rating Upgrade to Buy
All You Need to Know About LB Pharmaceuticals Inc (LBRX) Rating Upgrade to Buy
LBRX

Insiders Buy Over $98 Million in Biotech and Cybersecurity Shares in IPOs
Insiders Buy Over $98 Million in Biotech and Cybersecurity Shares in IPOs
LBRX

LB Pharma valued at $382 million as shares jump in New York debut
LB Pharma valued at $382 million as shares jump in New York debut
LBRX
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 52.43
- MACD 12/26/9
- -0.69
- EMA 9 of MACD
- -1.48
- MACD histogram
- 0.79
- SMA 50
- $42.29
- Price below SMA 50
- EMA 50
- $39.40
- Price above EMA 50
- SMA 200
- $31.99
- Price above SMA 200
- EMA 200
- $32.17
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 22, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 6 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
No data available
Debt & Balance Sheet
No data available
Revenue to Profit
No data available
Earnings
The market is expecting earnings per share of -$1.20 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

IPO Stock LB Pharma Has Tripled In Under A Year. Is It A Takeover Target?
IPO Stock LB Pharma Has Tripled In Under A Year. Is It A Takeover Target?
LBRX

All You Need to Know About LB Pharmaceuticals Inc (LBRX) Rating Upgrade to Buy
All You Need to Know About LB Pharmaceuticals Inc (LBRX) Rating Upgrade to Buy
LBRX

Insiders Buy Over $98 Million in Biotech and Cybersecurity Shares in IPOs
Insiders Buy Over $98 Million in Biotech and Cybersecurity Shares in IPOs
LBRX

LB Pharma valued at $382 million as shares jump in New York debut
LB Pharma valued at $382 million as shares jump in New York debut
LBRX

LB Pharmaceuticals raises $285 million in US IPO
LB Pharmaceuticals raises $285 million in US IPO
LBRX
News tone: automated (AI) classification of the article's content, not a price prediction.
About LB Pharmaceuticals Inc Common Stock
LB Pharmaceuticals, Inc. (ticker LBRX) is a clinical-stage biopharmaceutical company focused on developing therapies for neuropsychiatric disorders such as schizophrenia and bipolar depression. Its lead product candidate, LB-102, is a methylated derivative of amisulpride designed to offer improved dosing, safety, and efficacy profiles compared to existing treatments. Founded in 2015 and based in New York, the company has raised venture funding through Series C to support its clinical trials and product development.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Ms. Heather D. Turner Esq., J.D. | CEO & Director | 1973 |
| Mr. Joseph M. Miller CPA | Chief Financial Officer | 1974 |
| Mr. Gad Soffer | Chief Operating & Business Officer | 1977 |
| Ms. Minako Pazdera J.D., Ph.D. | General Counsel | — |
| Ms. Lindsay Beaupre | Senior VP of People & Culture | — |
| Dr. Richard A. Silva Ph.D. | Senior Vice President of Technical Operations | 1968 |
| Dr. James Rawls Pharm.D. | Senior Vice President of Regulatory Affairs | — |
| Ms. Ellen Rose | Senior Vice President of Corporate Affairs | — |
| Ms. Kaya Pai Panandiker Kamlesh | Chief Commercial Officer | 1977 |
| Mr. Christopher Zergebel | Senior Vice President of Clinical Operations | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of October 23, 2026
Technical indicators
- RSI 14
- 52.43
- MACD 12/26/9
- -0.69
- EMA 9 of MACD
- -1.48
- MACD histogram
- 0.79
- SMA 50
- $42.29
- Price below SMA 50
- EMA 50
- $39.40
- Price above EMA 50
- SMA 200
- $31.99
- Price above SMA 200
- EMA 200
- $32.17
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 22, 2026. Technical data, not a recommendation.
Analyst views
6 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $35.00
- Average
- $60.33
- High
- $80.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | -8.7 | +2.3 | +10.0 | +27.7 | ||||||||
| 2026 | +4.9 | +4.8 | +3.7 | +27.8 | -11.0 | +15.8 | +25.7 | +10.3 | -18.5 | +5.7 |




